SIV viral vector-based alpha-1-antitrypsin replacement therapy (ID Pharma)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameSIV viral vector-based alpha-1-antitrypsin replacement therapy (ID Pharma)
Drug Alias NamerSIV.F/HN-hCEF-sohAAT
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy
Mechanisms of ActionAlpha-1-antiproteinase stimulants
TargetsAlpha-1-antiproteinase
Therapy Area/IndicationsRespiratory Tract Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesID Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesID Pharma Co Ltd
Active IndicationsN/A
Inactive IndicationsRespiratory Tract Diseases

Other Information

ATC CodeN/A
Related LinksN/A